Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Roche"


25 mentions found


The healthcare sector outperformed in Europe, India and China last month, according to Citi, which named its top picks worldwide. It gave Amylyx a price target of $53, giving it upside of around 88% from current levels. It gave Beam a price target of $60, implying upside of around 67%. Other European picks from Citi include Swiss healthcare company Roche and British pharma and biotech firm AstraZeneca . Asia stocks In Asia, Citi named Japanese pharmaceutical company Daiichi Sankyo , South Korean biotech firm Samsung Biologics and China's Wuxi Biologics as top picks.
FRANKFURT, May 10 (Reuters) - Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech (22UAy.DE) potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients. Pancreatic cancer is among the most deadly forms of cancer because it typically grows undetected until an effective treatment is too late. The trial focused on pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of pancreatic cancer cases. Nature covers a wide range of topics in science and technology beyond medicine. Among the eight trial participants with a detectable immune response, there was no evidence of cancer recurrence 18 months after surgery, while the median time to recurrence was 13.4 months among the non-responders.
China's yuan is gaining increasing usage globally, pointing to the de-dollarization of transactions worldwide — graduallyChina's yuan slid on Monday. Future Publishing/Getty ImagesThe US dollar has been the world's reserve currency since the second world war, playing an outsized role in the world's trade. Amid these dire tidings, the Chinese yuan is seizing the opportunity and is mounting a challenge to the dollar's dominance. Of course, it does create a desire on the part of China, of Russia, of Iran to find an alternative," Yelled said. Read further for five countries that have recently turned to the yuan for trade and other transactions — either to skirt sanctions or as an alternative to the greenback.
The drug recorded sales of $2.28 billion in the quarter, missing expectations of $2.43 billion, according to an average of six analysts' estimates polled by Refinitiv. The company has also been leaning on its anti-inflammatory drug Dupixent - a treatment currently approved for five indications including asthma and atopic dermatitis, or eczema. Quarterly sales of Dupixent, recorded by Regeneron's partner Sanofi (SASY.PA), rose about 37% to $2.49 billion, above expectations of $2.38 billion. Regeneron's total revenue of $3.16 billion beat estimates of $3 billion. Excluding items, the company reported a profit of $10.09 per share, above estimates of $9.56.
But time spent waiting robs early patients of their memory and ability to live independently. This condition is often, though not always, a sign of early Alzheimer's disease. PET scans cumbersomeTwo types of tests can diagnosis Alzheimer's disease: PET scans and spinal taps. Early Alzheimer's disease can also be diagnosed with a spinal tap, in which fluid around the spinal cord is extracted with a catheter and tested. He believes big players like CVS will provide infusions for Alzheimer's disease on a major scale if they see there's a large and stable market.
The best of Milan Design Week 2023
  + stars: | 2023-04-27 | by ( Marianna Cerini | ) edition.cnn.com   time to read: +8 min
Milan CNN —The design world’s largest annual fair enjoyed a return to full pre-pandemic form with its 2023 showcase, transforming the city of Milan with hundreds of exhibitions, site-specific installations, pop-ups and public projects. Almost everywhere, the focus was on sustainable design, circular economy, material innovation and artistry combining craft with innovation. Some of the most interesting ideas were those that looked at waste – literally – to rethink what design can do when it uses what is already there. Shown in various stages of decomposition, the chair challenged viewers to approach products with the end of their lifecycle in mind. Top image: One of two bags design legend Gaetano Pesce created for Bottega Veneta’s Milan Design Week installation.
Like the first ring around Quaoar, announced by a team of astronomers in February, the second ring lies beyond what is known as the Roche limit. Thus, a ring within the Roche limit would tend to remain a ring, while a ring of debris outside the Roche limit would usually coalesce into a moon. For Quaoar, the Roche limit is calculated to be 1,100 miles. The second ring, at a distance of 1,500 miles from the center of Quaoar, is closer than the ring announced in February, which has a radius of about 2,500 miles. The observations also revealed the second ring.
Bristol Myers CEO Caforio steps down
  + stars: | 2023-04-26 | by ( ) www.reuters.com   time to read: +1 min
[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File PhotoCompanies Bristol-Myers Squibb Co FollowApril 26 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Outgoing CEO Giovanni will continue as executive chairman of the company's board. Bristol Myers is due to report first-quarter financial results on Thursday. Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.
[1/2] The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. Quarterly group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating market expectations of 14.8 billion francs. The company, which does not report earnings for its first and third quarter, reiterated that pandemic-related sales - mainly lab testing, antibody treatment Ronapreve and repurposed arthritis drug Actemra - would drop by 5 billion francs this year. "We are very happy with the very rapid and significant uptake in the different markets around the world," he said on a media call. Sales and core earnings per share were still expected to decrease at a "low single-digit" percentage in 2023, the pharmaceuticals and diagnostics company added.
Roche Q1 sales down 7% as COVID-related business wanes
  + stars: | 2023-04-26 | by ( ) www.reuters.com   time to read: 1 min
April 26 (Reuters) - Swiss drugmaker Roche (ROG.S) said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and diagnostics kits. Quarterly group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating market expectations of 14.8 billion francs. The company does not report earnings for its first and third quarter. Reporting by Ludwig Burger, editing by Kirsti KnolleOur Standards: The Thomson Reuters Trust Principles.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew biomarkers, technologies and pharma products will fill Covid vacuum: Roche CEOThomas Schinecker, the CEO of Roche, discusses first-quarter earnings, and the new growth developments that will help mitigate the decrease in demand for Covid-19 related products.
April 23 (Reuters) - Belgian Remco Evenepoel claimed back-to-back wins in the Liege-Bastogne-Liege one-day race on Sunday with a stunning solo ride to victory while Slovenia's pre-race favourite Tadej Pogacar had to abandon the race after fracturing his wrist in a crash. Soudal Quick-Step's Evenepoel first attacked with about 34 km left with Ineos Grenadiers' Tom Pidcock joining him at the front. But Evenepoel attacked again on the next climb to leave the Briton behind with 30 km to go. My back wheel went a bit like it did last year (on a turn)," Evenepoel said. I said I wanted the picture with the jersey to put in my bedroom," Evenepoel added.
A home in Lynch, Kentucky. Central banks in Europe, the U.S. and the U.K. sprang into action to reassure that they would provide liquidity backstops, to prevent a domino effect and calm the markets. Roche, who correctly predicted the development of the Asian crisis in 1997 and the 2008 global financial crisis, argued that, alongside their efforts to rein in sky-high inflation, central banks are "trying to do two things at once." "They're trying to keep liquidity high, so that the problems of deposit withdrawals and other problems relating to mark-to-market of assets in banks do not cause more crises, more threats of systemic risk," he said. "At the same time, they're trying to tighten monetary policy, so, in a sense, you've got a schizophrenic personality of every central bank, which is doing with the right hand one thing and doing with the left hand the other thing."
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailVeteran investor David Roche sees further contraction of credit to 'small America'David Roche, president of Independent Strategy, discusses how recent turmoil in the banking sector may feed through to tighter credit conditions in the real economy, and how investors should position.
The list of top companies in Singapore sees a huge reshuffle this year, which is a testament to "Singapore's strong business ecosystem," according to LinkedIn. LinkedIn has released its annual list of top companies in Singapore to work for — and banking and information technology companies dominated the 2023 list. The list of top companies also saw a huge reshuffle this year, which is a testament to "Singapore's strong business ecosystem," according to the professional networking platform. The banking and finance sector in particular, saw 4 companies in the top 5 on the "LinkedIn Top Companies 2023″ for Singapore. It provides financial products and banking services to individuals, corporations, governments, investors and institutions.
Global central banks are less willing to hold the dollar, billionaire investor Ray Dalio said. One reason is that China's share of global trade is rising while the US share is falling. Another is that Western sanctions against Russia have exposed new risks for holding dollar assets. But, with China increasing the yuan's use in global trade, the future necessity for the greenback may be ebbing. Those sanctions "increased the perceived risk that those debt assets can be frozen in the way that they've been frozen for Russia," Dalio said.
REUTERS/Tom KaeckenhoffLEVERKUSEN, Germany, April 5 (Reuters) - Incoming Bayer (BAYGn.DE) chief executive Bill Anderson says he is keeping an open mind on whether to break up the company into smaller pieces, as some fidgety investors want. "That's why I said I am going to have an open mind," he said. On the stock market Bayer, once the most valuable company on Germany's DAX blue-chip index, is now worth only about the same as it paid for Monsanto. At Bayer, he said he did not have his own desk and made use of the company's meeting rooms as needed. Professing a love of American football, hiking and snowboarding, he was also effusive about Bayer as a company and its heritage of medicines such as Aspirin.
Investors should take a closer look at Disc Medicine as it develops treatments for blood disorders, according to BMO Capital Markets. Analyst Evan David Seigerman initiated coverage of Disc Medicine with an outperform rating and a $40 price target, saying that the firm's development of bitopertin to treat erythropoietic porphyrias and other blood disorders appears promising. IRON YTD mountain Disc Medicine shares YTD Last year, Disc Medicine went public in a reverse merger with biotechnology company Gemini Therapeutics, trading under the ticker symbol "IRON." Disc Medicine shares are up 8% this year. The analyst's $40 price target means that Disc Medicine shares can jump 84% from Wednesday's closing price.
Here are Thursday's biggest calls on Wall Street: Morgan Stanley reiterates Tesla as overweight Morgan Stanley said Tesla could eventually be a solution to vehicle affordability. Truist upgrades BellRing Brands to buy from hold Truist said the time is right to buy shares of the food products company. Citi moves First Republic to an under review rating Citi moved to an under review rating on First Republic due to too much uncertainty. Piper Sandler reiterates Meta and Pinterest as top picks Piper said it's standing by shares of Meta and Pinterest. Oppenheimer downgrades Coinbase to perform from outperform Oppenheimer said it sees an "unhealthy regulatory climate" for Coinbase.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe ECB is 'facing backwards' by hiking rates by 50 basis points, strategist saysDavid Roche, president and global strategist at Independent Strategy, says that the ECB is "facing backwards" by hiking rates by 50 basis points.
[1/2] Sign is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File PhotoMarch 17 (Reuters) - Shares of Sarepta Therapeutics Inc (SRPT.O) slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a panel meeting. The U.S. Food and Drug Administration planned to hold a meeting of its independent experts to review the gene therapy, the company said late on Thursday, less than a month after saying it would not do so. Sarepta is developing SRP-9001 as the first gene therapy for the treatment of Duchenne muscular dystrophy, an inherited disorder of progressive muscular weakness typically seen in boys. Gene therapies such as BioMarin's (BMRN.O) bleeding disorder therapy have faced setbacks and tough scrutiny in the past, but the FDA approved multiple such products in 2022.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche says a 'fault' of the European Central Bank is that it looks backwardDavid Roche, president of Independent Strategy, discusses the European Central Bank's decision to hike interest rates by 50 basis points.
Still, no matter what the Consumer Price Index clocks in at, it's possible that the failures of Signature Bank and Silicon Valley Bank already convinced Jerome Powell to take his foot off the gas. Silicon Valley Bank employees react to the bank's collapse Getty Images1. With the government rescuing Signature and Silicon Valley Bank depositors, not all the downside has been contained, according to Wharton finance professor, Itamar Drechsler. Silicon Valley Bank's CEO, Greg Becker, previously asked Congress to ease regulatory oversight on the bank. But, as Jefferies analysts put it, "the world changed" with Silicon Valley Bank's failure.
Novartis initiates new trading line for share buybacks
  + stars: | 2023-03-13 | by ( Ludwig Burger | ) www.reuters.com   time to read: +1 min
March 13 (Reuters) - Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion. At last week's annual shareholder meeting, the company won investor authorization for up to 10 billion francs in buybacks, which comes on top of 6.5 billion francs in prior authorizations. A company spokesperson told Reuters on Monday that the "majority" of its ongoing $15 billion buyback programme was already completed, adding that any repurchases would be decided by the board of directors. Novartis laid out plans for the $15 billion programme in late 2021, after receiving $20.7 billion for the sale of its nearly one-third voting stake in Roche (ROG.S) back to its cross-town rival. ($1 = 0.9118 Swiss francs)Reporting by Ludwig Burger in Frankfurt and John Revill in Zurich Editing by Paul Carrel and Christina FincherOur Standards: The Thomson Reuters Trust Principles.
Regeneron’s drug Eylea is used to treat retinal diseases. Leonard Schleifer , the longtime Regeneron boss, likes to point out that, unlike many giant drug companies gaming the healthcare system with all kinds of gimmicks, his biotech focuses on true innovation. The Tarrytown, N.Y.-based company has certainly developed therapies that have made a difference for patients suffering from difficult-to-treat illnesses. More recently, it was catapulted into the national spotlight during the pandemic thanks to its monoclonal antibody infusion for Covid-19.
Total: 25